Decreased tryptophan metabolism in patients with autism spectrum disorders
Autism spectrum disorders (ASDs) are relatively common neurodevelopmental conditions whose biological basis has been incompletely determined. Several biochemical markers have been associated with ASDs, but there is still no laboratory test for these conditions.
We analyzed the metabolic profile of lymphoblastoid cell lines from 137 patients with neurodevelopmental disorders with or without ASDs and 78 normal individuals, using Biolog Phenotype MicroArrays.
Metabolic profiling of lymphoblastoid cells revealed that the 87 patients with ASD as a clinical feature, as compared to the 78 controls, exhibited on average reduced generation of NADH when tryptophan was the sole energy source. The results correlated with the behavioral traits associated with either syndromal or non-syndromal autism, independent of the genetic background of the individual. The low level of NADH generation in the presence of tryptophan was not observed in cell lines from non-ASD patients with intellectual disability, schizophrenia or conditions exhibiting several similarities with syndromal autism except for the behavioral traits. Analysis of a previous small gene expression study found abnormal levels for some genes involved in tryptophan metabolic pathways in 10 patients.
Tryptophan is a precursor of important compounds, such as serotonin, quinolinic acid, and kynurenic acid, which are involved in neurodevelopment and synaptogenesis. In addition, quinolinic acid is the structural precursor of NAD+, a critical energy carrier in mitochondria. Also, the serotonin branch of the tryptophan metabolic pathway generates NADH. Lastly, the levels of quinolinic and kynurenic acid are strongly influenced by the activity of the immune system. Therefore, decreased tryptophan metabolism may alter brain development, neuroimmune activity and mitochondrial function. Our finding of decreased tryptophan metabolism appears to provide a unifying biochemical basis for ASDs and perhaps an initial step in the development of a diagnostic assay for ASDs.
- Autism and Developmental Disabilities Monitoring Network Surveillance Year 2006 Principal Investigators; Centers for Disease Control and Prevention (CDC): Prevalence of autism spectrum disorders - autism and developmental disabilities monitoring network, United States, 2006. MMWR Surveill Summ 2009, 58:1–20.
- Ganz ML: The lifetime distribution of the incremental societal costs of autism. Arch Pediatr Adolesc Med 2007, 161:343–349. CrossRef
- Valicenti-McDermott M, Hottinger K, Seijo R, Shulman L: Age at diagnosis of autism spectrum disorders. J Pediatr 2012, 161:554–556. CrossRef
- Schaefer GB, Mendelsohn NJ: Clinical genetics evaluation in identifying the etiology of autism spectrum disorders. Genet Med 2008, 10:301–305. CrossRef
- Miles JH: Autism spectrum disorders–a genetics review. Genet Med 2011, 13:278–294. CrossRef
- Anderson GM, Lombroso PJ: Genetics of childhood disorders: XLV. Autism, part 4: serotonin in autism. J Am Acad Child Adolesc Psychiatry 2002, 41:1513–1516. CrossRef
- Yap IK, Angley M, Veselkov KA, Holmes E, Lindon JC, Nicholson JK: Urinary metabolic phenotyping differentiates children with autism from their unaffected siblings and age-matched controls. J Proteome Res 2010, 9:2996–3004. CrossRef
- Adams JB, Audhya T, McDonough-Means S, Rubin RA, Quig D, Geis E, Gehn E, Loresto M, Mitchell J, Atwood S, Barnhouse S, Lee W: Nutritional and metabolic status of children with autism vs. neurotypical children, and the association with autism severity. Nutr Metab (Lond) 2011, 8:34. CrossRef
- Schroer RJ, Phelan MC, Michaelis RC, Crawford EC, Skinner SA, Cuccaro M, Simensen RJ, Bishop J, Skinner C, Fender D, Stevenson RE: Autism and maternally derived aberrations of chromosome 15q. Am J Med Genet 1998, 76:327–336. CrossRef
- Bochner BR, Siri M, Huang RH, Noble S, Lei XH, Clemons PA, Wagner BK: Assay of the multiple energy-producing pathways of mammalian cells. PLoS One 2011, 6:e18147. CrossRef
- Putluri N, Shojaie A, Vasu VT, Nalluri S, Vareed SK, Putluri V, Vivekanandan-Giri A, Byun J, Pennathur S, Sana TR, Fischer SM, Palapattu GS, Creighton CJ, Michailidis G, Sreekumar A: Metabolomic profiling reveals a role for androgen in activating amino acid metabolism and methylation in prostate cancer cells. PLoS One 2011, 6:e21417. CrossRef
- Hughes TR, Mao M, Jones AR, Burchard J, Marton MJ, Shannon KW, Lefkowitz SM, Ziman M, Schelter JM, Meyer MR, Kobayashi S, Davis C, Dai H, He YD, Stephaniants SB, Cavet G, Walker WL, West A, Coffey E, Shoemaker DD, Stoughton R, Blanchard AP, Friend SH, Linsley PS: Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer. Nat Biotechnol 2001, 19:342–347. CrossRef
- Churchill GA: Fundamentals of experimental design for cDNA microarrays. Nat Genet 2002, Suppl:490–495. CrossRef
- Tusher VG, Tibshirani R, Chu G: Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001, 98:5116–5121. CrossRef
- Storey JD, Tibshirani R: Statistical significance for genomewide studies. Proc Natl Acad Sci USA 2003, 100:9440–9445. CrossRef
- Witten IH, Eibe F: Data Mining: Practical Machine Learning Tools and Techniques. San Francisco, CA: Morgan Kaufman; 2005.
- Chen CF, Cheng CH: Regulation of cellular metabolism and cytokines by the medicinal herb feverfew in the human monocytic THP-1 cells. Evid Based Complement Alternat Med 2009, 6:91–98. CrossRef
- Stone TW, Darlington LG: Endogenous kynurenines as targets for drug discovery and development. Nat Rev Drug Discov 2002, 1:609–620. CrossRef
- Weiss LA, Shen Y, Korn JM, Arking DE, Miller DT, Fossdal R, Saemundsen E, Stefansson H, Ferreira MA, Green T, Platt OS, Ruderfer DM, Walsh CA, Altshuler D, Chakravarti A, Tanzi RE, Stefansson K, Santangelo SL, Gusella JF, Sklar P, Wu BL, Daly MJ, Autism Consortium: Association between microdeletion and microduplication at 16p11.2 and autism. N Engl J Med 2008, 358:667–675. CrossRef
- Rossignol DA, Frye RE: Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis. Mol Psychiatry 2012, 17:290–314. CrossRef
- Mattson MP, Liu D: Energetics and oxidative stress in synaptic plasticity and neurodegenerative disorders. Neuromolecular Med 2002, 2:215–231. CrossRef
- Anderson MP, Hooker BS, Herbert MR: Bridging from cells to cognition in autism pathophysiology: biological pathways to defective brain function and plasticity. Am J Biochem Biotechnol 2008, 4:167–176. CrossRef
- Bourgeron T: A synaptic trek to autism. Curr Opin Neurobiol 2009, 19:231–234. CrossRef
- Kelleher RJ 3rd, Bear MF: The autistic neuron: troubled translation? Cell 2008, 135:401–406. CrossRef
- Casanova MF: The neuropathology of autism. Brain Pathol 2007, 17:422–433. CrossRef
- Courchesne E, Mouton PR, Calhoun ME, Semendeferi K, Ahrens-Barbeau C, Hallet MJ, Barnes CC, Pierce K: Neuron number and size in prefrontal cortex of children with autism. JAMA 2011, 306:2001–2010. CrossRef
- Sweeten TL, Posey DJ, Shankar S, McDougle CJ: High nitric oxide production in autistic disorder: a possible role for interferon-gamma. Biol Psychiatry 2004, 55:434–437. CrossRef
- Sogut S, Zoroglu SS, Ozyurt H, Yilmaz HR, Ozugurlu F, Sivasli E, Yetkin O, Yanik M, Tutkun H, Savas HA, Tarakcioglu M, Aykol O: Changes in nitric oxide levels and antioxidant enzyme activities may have a role in the pathophysiological mechanisms involved in autism. Clin Chim Acta 2003, 331:111–117. CrossRef
- Barnes NM, Sharp T: A review of central 5-HT receptors and their function. Neuropharmacology 1999, 38:1083–1152. CrossRef
- Chugani DC, Muzik O, Behen M, Rothermel R, Janisse JJ, Lee J, Chugani HT: Developmental changes in brain serotonin synthesis capacity in autistic and nonautistic children. Ann Neurol 1999, 45:287–295. CrossRef
- Schaechter JD, Wurtman RJ: Serotonin release varies with brain tryptophan levels. Brain Res 1990, 532:203–210. CrossRef
- Moskowitz DS, Pinard G, Zuroff DC, Annable L, Young SN: The effect of tryptophan on social interaction in everyday life: a placebo-controlled study. Neuropsychopharmacology 2001, 25:277–289. CrossRef
- Johansson J, Landgren M, Fernell E, Vumma R, Ahlin A, Bjerkenstedt L, Venizelos N: Altered tryptophan and alanine transport in fibroblasts from boys with attention-deficit/hyperactivity disorder (ADHD): an in vitro study. Behav Brain Funct 2011, 7:40. CrossRef
- Sugden K, Tichopad A, Khan N, Craig IW, D’Souza UM: Genes within the serotonergic system are differentially expressed in human brain. BMC Neurosci 2009, 10:50. CrossRef
- Zill P, Buttner A, Eisenmenger W, Moller HJ, Ackenheil M, Bondy B: Analysis of tryptophan hydroxylase I and II mRNA expression in the human brain: a post-mortem study. J Psychiatr Res 2007, 41:168–173. CrossRef
- Daubert EA, Condron BG: Serotonin: a regulator of neuronal morphology and circuitry. Trends Neurosci 2010, 33:424–434. CrossRef
- Bonnin A, Goeden N, Chen K, Wilson ML, King J, Shih JC, Blakely RD, Deneris ES, Levitt P: A transient placental source of serotonin for the fetal forebrain. Nature 2011, 472:347–350. CrossRef
- Voineagu I, Wang X, Johnston P, Lowe JK, Tian Y, Horvath S, Mill J, Cantor RM, Blencowe BJ, Geschwind DH: Transcriptomic analysis of autistic brain reveals convergent molecular pathology. Nature 2011, 474:380–384. CrossRef
- Casanova MF, van Kooten IA, Switala AE, van Engeland H, Heinsen H, Steinbusch HW, Hof PR, Trippe J, Stone J, Schmitz C: Minicolumnar abnormalities in autism. Acta Neuropathol 2006, 112:287–303. CrossRef
- Minshew NJ, Williams DL: The new neurobiology of autism: cortex, connectivity, and neuronal organization. Arch Neurol 2007, 64:945–950. CrossRef
- Decreased tryptophan metabolism in patients with autism spectrum disorders
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
- Online Date
- June 2013
- Online ISSN
- BioMed Central
- Additional Links
- Author Affiliations
- 3. Greenwood Genetic Center, 113 Gregor Mendel Circle, Greenwood, SC, 29646, USA
- 4. Biolog, Inc, 21124 Cabot Boulevard, Hayward, CA, 94545, USA